Drugs for Vulvovaginal Candidiasis Market - Global Outlook and Forecast 2021-2027

January 2021 | 91 pages | ID: D857CA900ED2EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Drugs for Vulvovaginal Candidiasis in global, including the following market information:
Global Drugs for Vulvovaginal Candidiasis Market Revenue, 2016-2021, 2022-2027, ($ millions)
Global Drugs for Vulvovaginal Candidiasis Market Sales, 2016-2021, 2022-2027, (K Units)
Global top five Drugs for Vulvovaginal Candidiasis companies in 2020 (%)
The global Drugs for Vulvovaginal Candidiasis market was valued at 827.8 million in 2020 and is projected to reach US$ 876.4 million by 2027, at a CAGR of 1.4% during the forecast period.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Drugs for Vulvovaginal Candidiasis manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Drugs for Vulvovaginal Candidiasis Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Units)
Global Drugs for Vulvovaginal Candidiasis Market Segment Percentages, By Type, 2020 (%)

• Miconazole
• Clotrimazole
• Fluconazole
• Econazole
• Other

Global Drugs for Vulvovaginal Candidiasis Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Units)
Global Drugs for Vulvovaginal Candidiasis Market Segment Percentages, By Application, 2020 (%)

• Hospital & Clinic
• Pharmacy

Global Drugs for Vulvovaginal Candidiasis Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions) & (K Units)
Global Drugs for Vulvovaginal Candidiasis Market Segment Percentages, By Region and Country, 2020 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Drugs for Vulvovaginal Candidiasis revenues in global market, 2016-2021 (Estimated), ($ millions)
Key companies Drugs for Vulvovaginal Candidiasis revenues share in global market, 2020 (%)
Key companies Drugs for Vulvovaginal Candidiasis sales in global market, 2016-2021 (Estimated), (K Units)
Key companies Drugs for Vulvovaginal Candidiasis sales share in global market, 2020 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Bayer
• Perrigo
• J & J
• Pfizer
• Bristol-Myers Squibb
• Effik
• Teva
• Sanofi
• Cisen Pharmaceutical
• Kingyork Group

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Drugs for Vulvovaginal Candidiasis Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Drugs for Vulvovaginal Candidiasis Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL DRUGS FOR VULVOVAGINAL CANDIDIASIS OVERALL MARKET SIZE

2.1 Global Drugs for Vulvovaginal Candidiasis Market Size: 2021 VS 2027
2.2 Global Drugs for Vulvovaginal Candidiasis Revenue, Prospects & Forecasts: 2016-2027
2.3 Global Drugs for Vulvovaginal Candidiasis Sales (Consumption): 2016-2027

3 COMPANY LANDSCAPE

3.1 Top Drugs for Vulvovaginal Candidiasis Players in Global Market
3.2 Top Global Drugs for Vulvovaginal Candidiasis Companies Ranked by Revenue
3.3 Global Drugs for Vulvovaginal Candidiasis Revenue by Companies
3.4 Global Drugs for Vulvovaginal Candidiasis Sales by Companies
3.5 Global Drugs for Vulvovaginal Candidiasis Price by Manufacturer (2016-2021)
3.6 Top 3 and Top 5 Drugs for Vulvovaginal Candidiasis Companies in Global Market, by Revenue in 2020
3.7 Global Manufacturers Drugs for Vulvovaginal Candidiasis Product Type
3.8 Tier 1, Tier 2 and Tier 3 Drugs for Vulvovaginal Candidiasis Players in Global Market
  3.8.1 List of Global Tier 1 Drugs for Vulvovaginal Candidiasis Companies
  3.8.2 List of Global Tier 2 and Tier 3 Drugs for Vulvovaginal Candidiasis Companies

4 SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - Global Drugs for Vulvovaginal Candidiasis Market Size Markets, 2021 & 2027
  4.1.2 Miconazole
  4.1.3 Clotrimazole
  4.1.4 Fluconazole
  4.1.5 Econazole
  4.1.6 Other
4.2 By Type - Global Drugs for Vulvovaginal Candidiasis Revenue & Forecasts
  4.2.1 By Type - Global Drugs for Vulvovaginal Candidiasis Revenue, 2016-2021
  4.2.2 By Type - Global Drugs for Vulvovaginal Candidiasis Revenue, 2022-2027
  4.2.3 By Type - Global Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2016-2027
4.3 By Type - Global Drugs for Vulvovaginal Candidiasis Sales & Forecasts
  4.3.1 By Type - Global Drugs for Vulvovaginal Candidiasis Sales, 2016-2021
  4.3.2 By Type - Global Drugs for Vulvovaginal Candidiasis Sales, 2022-2027
  4.3.3 By Type - Global Drugs for Vulvovaginal Candidiasis Sales Market Share, 2016-2027
4.4 By Type - Global Drugs for Vulvovaginal Candidiasis Price (Manufacturers Selling Prices), 2016-2027

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Drugs for Vulvovaginal Candidiasis Market Size, 2021 & 2027
  5.1.2 Hospital & Clinic
  5.1.3 Pharmacy
5.2 By Application - Global Drugs for Vulvovaginal Candidiasis Revenue & Forecasts
  5.2.1 By Application - Global Drugs for Vulvovaginal Candidiasis Revenue, 2016-2021
  5.2.2 By Application - Global Drugs for Vulvovaginal Candidiasis Revenue, 2022-2027
  5.2.3 By Application - Global Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2016-2027
5.3 By Application - Global Drugs for Vulvovaginal Candidiasis Sales & Forecasts
  5.3.1 By Application - Global Drugs for Vulvovaginal Candidiasis Sales, 2016-2021
  5.3.2 By Application - Global Drugs for Vulvovaginal Candidiasis Sales, 2022-2027
  5.3.3 By Application - Global Drugs for Vulvovaginal Candidiasis Sales Market Share, 2016-2027
5.4 By Application - Global Drugs for Vulvovaginal Candidiasis Price (Manufacturers Selling Prices), 2016-2027

6 SIGHTS BY REGION

6.1 By Region - Global Drugs for Vulvovaginal Candidiasis Market Size, 2021 & 2027
6.2 By Region - Global Drugs for Vulvovaginal Candidiasis Revenue & Forecasts
  6.2.1 By Region - Global Drugs for Vulvovaginal Candidiasis Revenue, 2016-2021
  6.2.2 By Region - Global Drugs for Vulvovaginal Candidiasis Revenue, 2022-2027
  6.2.3 By Region - Global Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2016-2027
6.3 By Region - Global Drugs for Vulvovaginal Candidiasis Sales & Forecasts
  6.3.1 By Region - Global Drugs for Vulvovaginal Candidiasis Sales, 2016-2021
  6.3.2 By Region - Global Drugs for Vulvovaginal Candidiasis Sales, 2022-2027
  6.3.3 By Region - Global Drugs for Vulvovaginal Candidiasis Sales Market Share, 2016-2027
6.4 North America
  6.4.1 By Country - North America Drugs for Vulvovaginal Candidiasis Revenue, 2016-2027
  6.4.2 By Country - North America Drugs for Vulvovaginal Candidiasis Sales, 2016-2027
  6.4.3 US Drugs for Vulvovaginal Candidiasis Market Size, 2016-2027
  6.4.4 Canada Drugs for Vulvovaginal Candidiasis Market Size, 2016-2027
  6.4.5 Mexico Drugs for Vulvovaginal Candidiasis Market Size, 2016-2027
6.5 Europe
  6.5.1 By Country - Europe Drugs for Vulvovaginal Candidiasis Revenue, 2016-2027
  6.5.2 By Country - Europe Drugs for Vulvovaginal Candidiasis Sales, 2016-2027
  6.5.3 Germany Drugs for Vulvovaginal Candidiasis Market Size, 2016-2027
  6.5.4 France Drugs for Vulvovaginal Candidiasis Market Size, 2016-2027
  6.5.5 U.K. Drugs for Vulvovaginal Candidiasis Market Size, 2016-2027
  6.5.6 Italy Drugs for Vulvovaginal Candidiasis Market Size, 2016-2027
  6.5.7 Russia Drugs for Vulvovaginal Candidiasis Market Size, 2016-2027
  6.5.8 Nordic Countries Drugs for Vulvovaginal Candidiasis Market Size, 2016-2027
  6.5.9 Benelux Drugs for Vulvovaginal Candidiasis Market Size, 2016-2027
6.6 Asia
  6.6.1 By Region - Asia Drugs for Vulvovaginal Candidiasis Revenue, 2016-2027
  6.6.2 By Region - Asia Drugs for Vulvovaginal Candidiasis Sales, 2016-2027
  6.6.3 China Drugs for Vulvovaginal Candidiasis Market Size, 2016-2027
  6.6.4 Japan Drugs for Vulvovaginal Candidiasis Market Size, 2016-2027
  6.6.5 South Korea Drugs for Vulvovaginal Candidiasis Market Size, 2016-2027
  6.6.6 Southeast Asia Drugs for Vulvovaginal Candidiasis Market Size, 2016-2027
  6.6.7 India Drugs for Vulvovaginal Candidiasis Market Size, 2016-2027
6.7 South America
  6.7.1 By Country - South America Drugs for Vulvovaginal Candidiasis Revenue, 2016-2027
  6.7.2 By Country - South America Drugs for Vulvovaginal Candidiasis Sales, 2016-2027
  6.7.3 Brazil Drugs for Vulvovaginal Candidiasis Market Size, 2016-2027
  6.7.4 Argentina Drugs for Vulvovaginal Candidiasis Market Size, 2016-2027
6.8 Middle East & Africa
  6.8.1 By Country - Middle East & Africa Drugs for Vulvovaginal Candidiasis Revenue, 2016-2027
  6.8.2 By Country - Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales, 2016-2027
  6.8.3 Turkey Drugs for Vulvovaginal Candidiasis Market Size, 2016-2027
  6.8.4 Israel Drugs for Vulvovaginal Candidiasis Market Size, 2016-2027
  6.8.5 Saudi Arabia Drugs for Vulvovaginal Candidiasis Market Size, 2016-2027
  6.8.6 UAE Drugs for Vulvovaginal Candidiasis Market Size, 2016-2027

7 MANUFACTURERS & BRANDS PROFILES

7.1 Bayer
  7.1.1 Bayer Corporate Summary
  7.1.2 Bayer Business Overview
  7.1.3 Bayer Drugs for Vulvovaginal Candidiasis Major Product Offerings
  7.1.4 Bayer Drugs for Vulvovaginal Candidiasis Sales and Revenue in Global (2016-2021)
  7.1.5 Bayer Key News
7.2 Perrigo
  7.2.1 Perrigo Corporate Summary
  7.2.2 Perrigo Business Overview
  7.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Major Product Offerings
  7.2.4 Perrigo Drugs for Vulvovaginal Candidiasis Sales and Revenue in Global (2016-2021)
  7.2.5 Perrigo Key News
7.3 J & J
  7.3.1 J & J Corporate Summary
  7.3.2 J & J Business Overview
  7.3.3 J & J Drugs for Vulvovaginal Candidiasis Major Product Offerings
  7.3.4 J & J Drugs for Vulvovaginal Candidiasis Sales and Revenue in Global (2016-2021)
  7.3.5 J & J Key News
7.4 Pfizer
  7.4.1 Pfizer Corporate Summary
  7.4.2 Pfizer Business Overview
  7.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Major Product Offerings
  7.4.4 Pfizer Drugs for Vulvovaginal Candidiasis Sales and Revenue in Global (2016-2021)
  7.4.5 Pfizer Key News
7.5 Bristol-Myers Squibb
  7.5.1 Bristol-Myers Squibb Corporate Summary
  7.5.2 Bristol-Myers Squibb Business Overview
  7.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Major Product Offerings
  7.5.4 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales and Revenue in Global (2016-2021)
  7.5.5 Bristol-Myers Squibb Key News
7.6 Effik
  7.6.1 Effik Corporate Summary
  7.6.2 Effik Business Overview
  7.6.3 Effik Drugs for Vulvovaginal Candidiasis Major Product Offerings
  7.6.4 Effik Drugs for Vulvovaginal Candidiasis Sales and Revenue in Global (2016-2021)
  7.6.5 Effik Key News
7.7 Teva
  7.7.1 Teva Corporate Summary
  7.7.2 Teva Business Overview
  7.7.3 Teva Drugs for Vulvovaginal Candidiasis Major Product Offerings
  7.4.4 Teva Drugs for Vulvovaginal Candidiasis Sales and Revenue in Global (2016-2021)
  7.7.5 Teva Key News
7.8 Sanofi
  7.8.1 Sanofi Corporate Summary
  7.8.2 Sanofi Business Overview
  7.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Major Product Offerings
  7.8.4 Sanofi Drugs for Vulvovaginal Candidiasis Sales and Revenue in Global (2016-2021)
  7.8.5 Sanofi Key News
7.9 Cisen Pharmaceutical
  7.9.1 Cisen Pharmaceutical Corporate Summary
  7.9.2 Cisen Pharmaceutical Business Overview
  7.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Major Product Offerings
  7.9.4 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales and Revenue in Global (2016-2021)
  7.9.5 Cisen Pharmaceutical Key News
7.10 Kingyork Group
  7.10.1 Kingyork Group Corporate Summary
  7.10.2 Kingyork Group Business Overview
  7.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Major Product Offerings
  7.10.4 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales and Revenue in Global (2016-2021)
  7.10.5 Kingyork Group Key News

8 GLOBAL DRUGS FOR VULVOVAGINAL CANDIDIASIS PRODUCTION CAPACITY, ANALYSIS

8.1 Global Drugs for Vulvovaginal Candidiasis Production Capacity, 2016-2027
8.2 Drugs for Vulvovaginal Candidiasis Production Capacity of Key Manufacturers in Global Market
8.3 Global Drugs for Vulvovaginal Candidiasis Production by Region

9 KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS

9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints

10 DRUGS FOR VULVOVAGINAL CANDIDIASIS SUPPLY CHAIN ANALYSIS

10.1 Drugs for Vulvovaginal Candidiasis Industry Value Chain
10.2 Drugs for Vulvovaginal Candidiasis Upstream Market
10.3 Drugs for Vulvovaginal Candidiasis Downstream and Clients
10.4 Marketing Channels Analysis
  10.4.1 Marketing Channels
  10.4.2 Drugs for Vulvovaginal Candidiasis Distributors and Sales Agents in Global

11 CONCLUSION

12 APPENDIX

12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Key Players of Drugs for Vulvovaginal Candidiasis in Global Market
Table 2. Top Drugs for Vulvovaginal Candidiasis Players in Global Market, Ranking by Revenue (2019)
Table 3. Global Drugs for Vulvovaginal Candidiasis Revenue by Companies, (US$, Mn), 2016-2021
Table 4. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Companies, 2016-2021
Table 5. Global Drugs for Vulvovaginal Candidiasis Sales by Companies, (K Units), 2016-2021
Table 6. Global Drugs for Vulvovaginal Candidiasis Sales Share by Companies, 2016-2021
Table 7. Key Manufacturers Drugs for Vulvovaginal Candidiasis Price (2016-2021) & (USD/Unit)
Table 8. Global Manufacturers Drugs for Vulvovaginal Candidiasis Product Type
Table 9. List of Global Tier 1 Drugs for Vulvovaginal Candidiasis Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Drugs for Vulvovaginal Candidiasis Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type – Global Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2021 VS 2027
Table 12. By Type - Global Drugs for Vulvovaginal Candidiasis Revenue (US$, Mn), 2016-2021
Table 13. By Type - Global Drugs for Vulvovaginal Candidiasis Revenue (US$, Mn), 2022-2027
Table 14. By Type - Global Drugs for Vulvovaginal Candidiasis Sales (K Units), 2016-2021
Table 15. By Type - Global Drugs for Vulvovaginal Candidiasis Sales (K Units), 2022-2027
Table 16. By Application – Global Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2021 VS 2027
Table 17. By Application - Global Drugs for Vulvovaginal Candidiasis Revenue (US$, Mn), 2016-2021
Table 18. By Application - Global Drugs for Vulvovaginal Candidiasis Revenue (US$, Mn), 2022-2027
Table 19. By Application - Global Drugs for Vulvovaginal Candidiasis Sales (K Units), 2016-2021
Table 20. By Application - Global Drugs for Vulvovaginal Candidiasis Sales (K Units), 2022-2027
Table 21. By Region – Global Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2021 VS 2027
Table 22. By Region - Global Drugs for Vulvovaginal Candidiasis Revenue (US$, Mn), 2016-2021
Table 23. By Region - Global Drugs for Vulvovaginal Candidiasis Revenue (US$, Mn), 2022-2027
Table 24. By Region - Global Drugs for Vulvovaginal Candidiasis Sales (K Units), 2016-2021
Table 25. By Region - Global Drugs for Vulvovaginal Candidiasis Sales (K Units), 2022-2027
Table 26. By Country - North America Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2021
Table 27. By Country - North America Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2022-2027
Table 28. By Country - North America Drugs for Vulvovaginal Candidiasis Sales, (K Units), 2016-2021
Table 29. By Country - North America Drugs for Vulvovaginal Candidiasis Sales, (K Units), 2022-2027
Table 30. By Country - Europe Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2021
Table 31. By Country - Europe Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2022-2027
Table 32. By Country - Europe Drugs for Vulvovaginal Candidiasis Sales, (K Units), 2016-2021
Table 33. By Country - Europe Drugs for Vulvovaginal Candidiasis Sales, (K Units), 2022-2027
Table 34. By Region - Asia Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2021
Table 35. By Region - Asia Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2022-2027
Table 36. By Region - Asia Drugs for Vulvovaginal Candidiasis Sales, (K Units), 2016-2021
Table 37. By Region - Asia Drugs for Vulvovaginal Candidiasis Sales, (K Units), 2022-2027
Table 38. By Country - South America Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2021
Table 39. By Country - South America Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2022-2027
Table 40. By Country - South America Drugs for Vulvovaginal Candidiasis Sales, (K Units), 2016-2021
Table 41. By Country - South America Drugs for Vulvovaginal Candidiasis Sales, (K Units), 2022-2027
Table 42. By Country - Middle East & Africa Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2021
Table 43. By Country - Middle East & Africa Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2022-2027
Table 44. By Country - Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales, (K Units), 2016-2021
Table 45. By Country - Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales, (K Units), 2022-2027
Table 46. Bayer Corporate Summary
Table 47. Bayer Drugs for Vulvovaginal Candidiasis Product Offerings
Table 48. Bayer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2016-2021)
Table 49. Perrigo Corporate Summary
Table 50. Perrigo Drugs for Vulvovaginal Candidiasis Product Offerings
Table 51. Perrigo Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2016-2021)
Table 52. J & J Corporate Summary
Table 53. J & J Drugs for Vulvovaginal Candidiasis Product Offerings
Table 54. J & J Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2016-2021)
Table 55. Pfizer Corporate Summary
Table 56. Pfizer Drugs for Vulvovaginal Candidiasis Product Offerings
Table 57. Pfizer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2016-2021)
Table 58. Bristol-Myers Squibb Corporate Summary
Table 59. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Product Offerings
Table 60. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2016-2021)
Table 61. Effik Corporate Summary
Table 62. Effik Drugs for Vulvovaginal Candidiasis Product Offerings
Table 63. Effik Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2016-2021)
Table 64. Teva Corporate Summary
Table 65. Teva Drugs for Vulvovaginal Candidiasis Product Offerings
Table 66. Teva Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2016-2021)
Table 67. Sanofi Corporate Summary
Table 68. Sanofi Drugs for Vulvovaginal Candidiasis Product Offerings
Table 69. Sanofi Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2016-2021)
Table 70. Cisen Pharmaceutical Corporate Summary
Table 71. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Product Offerings
Table 72. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2016-2021)
Table 73. Kingyork Group Corporate Summary
Table 74. Kingyork Group Drugs for Vulvovaginal Candidiasis Product Offerings
Table 75. Kingyork Group Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2016-2021)
Table 76. Drugs for Vulvovaginal Candidiasis Production Capacity (K Units) of Key Manufacturers in Global Market, 2019-2021 (K Units)
Table 77. Global Drugs for Vulvovaginal Candidiasis Capacity Market Share of Key Manufacturers, 2019-2021
Table 78. Global Drugs for Vulvovaginal Candidiasis Production by Region, 2016-2021 (K Units)
Table 79. Global Drugs for Vulvovaginal Candidiasis Production by Region, 2022-2027 (K Units)
Table 80. Drugs for Vulvovaginal Candidiasis Market Opportunities & Trends in Global Market
Table 81. Drugs for Vulvovaginal Candidiasis Market Drivers in Global Market
Table 82. Drugs for Vulvovaginal Candidiasis Market Restraints in Global Market
Table 83. Drugs for Vulvovaginal Candidiasis Raw Materials
Table 84. Drugs for Vulvovaginal Candidiasis Raw Materials Suppliers in Global Market
Table 85. Typical Drugs for Vulvovaginal Candidiasis Downstream
Table 86. Drugs for Vulvovaginal Candidiasis Downstream Clients in Global Market
Table 87. Drugs for Vulvovaginal Candidiasis Distributors and Sales Agents in Global Market

List Of Figures

LIST OF FIGURES

Figure 1. Drugs for Vulvovaginal Candidiasis Segment by Type
Figure 2. Drugs for Vulvovaginal Candidiasis Segment by Application
Figure 3. Global Drugs for Vulvovaginal Candidiasis Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Drugs for Vulvovaginal Candidiasis Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. Global Drugs for Vulvovaginal Candidiasis Revenue, 2016-2027 (US$, Mn)
Figure 7. Drugs for Vulvovaginal Candidiasis Sales in Global Market: 2016-2027 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Drugs for Vulvovaginal Candidiasis Revenue in 2020
Figure 9. By Type - Global Drugs for Vulvovaginal Candidiasis Sales Market Share, 2016-2027
Figure 10. By Type - Global Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2016-2027
Figure 11. By Type - Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit), 2016-2027
Figure 12. By Application - Global Drugs for Vulvovaginal Candidiasis Sales Market Share, 2016-2027
Figure 13. By Application - Global Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2016-2027
Figure 14. By Application - Global Drugs for Vulvovaginal Candidiasis Price (USD/Unit), 2016-2027
Figure 15. By Region - Global Drugs for Vulvovaginal Candidiasis Sales Market Share, 2016-2027
Figure 16. By Region - Global Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2016-2027
Figure 17. By Country - North America Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2016-2027
Figure 18. By Country - North America Drugs for Vulvovaginal Candidiasis Sales Market Share, 2016-2027
Figure 19. US Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2027
Figure 20. Canada Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2027
Figure 21. Mexico Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2027
Figure 22. By Country - Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2016-2027
Figure 23. By Country - Europe Drugs for Vulvovaginal Candidiasis Sales Market Share, 2016-2027
Figure 24. Germany Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2027
Figure 25. France Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2027
Figure 26. U.K. Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2027
Figure 27. Italy Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2027
Figure 28. Russia Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2027
Figure 29. Nordic Countries Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2027
Figure 30. Benelux Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2027
Figure 31. By Region - Asia Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2016-2027
Figure 32. By Region - Asia Drugs for Vulvovaginal Candidiasis Sales Market Share, 2016-2027
Figure 33. China Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2027
Figure 34. Japan Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2027
Figure 35. South Korea Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2027
Figure 36. Southeast Asia Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2027
Figure 37. India Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2027
Figure 38. By Country - South America Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2016-2027
Figure 39. By Country - South America Drugs for Vulvovaginal Candidiasis Sales Market Share, 2016-2027
Figure 40. Brazil Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2027
Figure 41. Argentina Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2027
Figure 42. By Country - Middle East & Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share, 2016-2027
Figure 43. By Country - Middle East & Africa Drugs for Vulvovaginal Candidiasis Sales Market Share, 2016-2027
Figure 44. Turkey Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2027
Figure 45. Israel Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2027
Figure 46. Saudi Arabia Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2027
Figure 47. UAE Drugs for Vulvovaginal Candidiasis Revenue, (US$, Mn), 2016-2027
Figure 48. Global Drugs for Vulvovaginal Candidiasis Production Capacity (K Units), 2016-2027
Figure 49. The Percentage of Production Drugs for Vulvovaginal Candidiasis by Region, 2020 VS 2027
Figure 50. Drugs for Vulvovaginal Candidiasis Industry Value Chain
Figure 51. Marketing Channels